We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
-2.49%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$302M
AUM Growth
+$12.4M
Cap. Flow
+$26.9M
Cap. Flow %
8.89%
Top 10 Hldgs %
96.77%
Holding
14
New
1
Increased
7
Reduced
6
Closed
–

Top Buys

Rank Stock Value
1
EMBC icon
Embecta
EMBC
+$29.3M
2
CAH icon
Cardinal Health
CAH
+$9.41M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$4.12M
4
BIIB icon
Biogen
BIIB
+$1.21M
5
KOD icon
Kodiak Sciences
KOD
+$728K

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$13.2M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.22M
3
ALKS icon
Alkermes
ALKS
+$748K
4
EXEL icon
Exelixis
EXEL
+$485K
5
UTHR icon
United Therapeutics
UTHR
+$78.1K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.8B
$47.4M 15.68%
201,228
-384
-0.2% -$78.1K
ALKS icon
2
Alkermes
ALKS
$8.22B
$41.7M 13.77%
1,398,159
-26,045
-2% -$748K
REGN icon
3
Regeneron Pharmaceuticals
REGN
$78.5B
$35.7M 11.8%
60,384
-6,496
-10% -$4.22M
EXEL icon
4
Exelixis
EXEL
$13.3B
$31.4M 10.37%
1,506,885
-23,521
-2% -$485K
ENTA icon
5
Enanta Pharmaceuticals
ENTA
$366M
$29.5M 9.76%
624,768
+75,940
+14% +$4.12M
MCK icon
6
McKesson
MCK
$100B
$27M 8.94%
82,894
-41,271
-33% -$13.2M
EMBC icon
7
Embecta
EMBC
$216M
$25.8M 8.51%
+1,017,194
New +$29.3M
BIIB icon
8
Biogen
BIIB
$30B
$23.9M 7.9%
117,248
+5,895
+5% +$1.21M
TARO
9
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$21M 6.94%
580,524
+14,573
+3% +$556K
CAH icon
10
Cardinal Health
CAH
$53.9B
$9.35M 3.09%
178,839
+165,639
+1,255% +$9.41M
EGRX
11
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$5.38M 1.78%
121,014
+6,227
+5% +$286K
KOD icon
12
Kodiak Sciences
KOD
$2.6B
$4.23M 1.4%
554,192
+103,592
+23% +$728K
NXTC icon
13
NextCure
NXTC
$16.8M
$146K 0.05%
2,583
+34
+1% +$1.78K
ASMB icon
14
Assembly Biosciences
ASMB
$498M
$21K 0.01%
832
-10
-1% -$230

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q2 2022 Portfolio in Review

As of Q2 2022, Krensavage Asset Management held 14 positions worth $302M, up 4.3% from $290M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Krensavage Asset Management deployed $26.9M of net new capital in Q2 2022, opening 1 new position and adding to 7 existing holdings. Its largest new stake was Embecta: 1,017,194 shares worth $25.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was McKesson, an estimated $13.2M trimmed.

  • Krensavage Asset Management's largest Q2 2022 buy was Embecta: 1,017,194 shares worth $25.8M.
  • Krensavage Asset Management added most to Cardinal Health in Q2 2022, an estimated $9.41M increase.
  • Krensavage Asset Management's biggest Q2 2022 reduction was McKesson, cutting an estimated $13.2M.
  • Krensavage Asset Management's ten largest holdings make up 97% of its $302M portfolio in Q2 2022.
  • Krensavage Asset Management opened 1 new position and closed 0 in Q2 2022.
  • Krensavage Asset Management's portfolio value rose 4.3% quarter-over-quarter to $302M.

Based on Krensavage Asset Management's 13F filing for Q2 2022, filed 16 Aug 2022.